BAKX Therapeutics

• 18/11/2021
• Series A
• $25,000,000

We create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and computational simulations

We have built an integrated & iterative platform based on knowledge, experimentation, and simulation that allows us to better interrogate and harness the power of regulated apoptosis

We are developing a suite of orally active therapeutics which can act as single agents or in combination with other oncology therapies to create better and lasting outcomes for cancer patients

---

---